BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17889708)

  • 1. Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia.
    Vaz de Campos MG; Montesano FT; Rodrigues MM; Chauffaille Mde L
    Cancer Genet Cytogenet; 2007 Oct; 178(1):49-56. PubMed ID: 17889708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletions of the 3'BCR and 5'ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells.
    Fournier M; Lacrosse S; Jamar M; Bours V; Herens C
    Cancer Genet Cytogenet; 2005 Jul; 160(2):184-7. PubMed ID: 15993277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.
    Bennour A; Ouahchi I; Ben Youssef Y; Zaier M; Laatiri MA; Harrabi I; Meddeb B; Elloumi M; Khelif A; Saad A; Sennana H
    Med Oncol; 2012 Jun; 29(2):1151-60. PubMed ID: 21461967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia.
    Douet-Guilbert N; Morel F; Quemener S; Maguer A; Le Bris MJ; Morice P; Berthou C; De Braekeleer M
    Cancer Genet Cytogenet; 2006 Oct; 170(2):89-92. PubMed ID: 17011977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia.
    Lee YK; Kim YR; Min HC; Oh BR; Kim TY; Kim YS; Cho HI; Kim HC; Lee YS; Lee DS
    Cancer Genet Cytogenet; 2006 Apr; 166(1):65-73. PubMed ID: 16616113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase.
    Li JY; Xu W; Wu W; Zhu Y; Qiu HR; Zhang R; Zhang SJ; Qian SX
    Onkologie; 2008 Nov; 31(11):585-9. PubMed ID: 19145090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of deletion of derivative chromosome 9 in patients with Ph+ chronic myeloid leukemia].
    Wu W; Xue YQ; Wu YF; Pan JL; Shen J
    Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):183-6. PubMed ID: 16792921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for deletion of 9q as a two-step process in chronic myeloid leukemia.
    Rudduck-Sivaswaren C; Tien SL; Lim P; Lim E; Lie DK; Tan PH; Lee AS
    Clin Genet; 2005 Nov; 68(5):461-5. PubMed ID: 16207215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of the 5'ABL region in Philadelphia chromosome positive chronic myeloid leukemia: frequency, origin and prognosis.
    Morel F; Ka C; Le Bris MJ; Herry A; Morice P; Bourquard P; Abgrall JF; Berthou C; De Braekeleer M
    Leuk Lymphoma; 2003 Aug; 44(8):1333-8. PubMed ID: 12952226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Home-brew" FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia.
    Albano F; Anelli L; Zagaria A; Archidiacono N; Liso V; Specchia G; Rocchi M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):121-6. PubMed ID: 17452253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
    Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis.
    Aoun P; Wiggins M; Pickering D; Foran J; Rasheed H; Pavletic SZ; Sanger W
    Cancer Genet Cytogenet; 2004 Oct; 154(2):138-43. PubMed ID: 15474149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique secondary chromosomal abnormalities are frequently found in the chronic phase of chronic myeloid leukemia in southern Vietnam.
    Phan TX; Hoang AV; Huynh VM; Nguyen KT; Nguyen TB; Huynh N; Pham QT; Tran VB; Tran VB; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jul; 168(1):59-68. PubMed ID: 16772122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia.
    Xinh PT; Vu HA; Nghia H; Binh NT; Van Be T; Van Binh T; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jan; 164(2):122-7. PubMed ID: 16434314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
    Roti G; La Starza R; Gorello P; Gottardi E; Crescenzi B; Martelli MF; Mecucci C
    Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia.
    Yoong Y; VanDeWalker TJ; Carlson RO; Dewald GW; Tefferi A
    Eur J Haematol; 2005 Feb; 74(2):124-7. PubMed ID: 15654903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dual colour dual fusion fluorescence in situ hybridisation study on the genesis of complex variant translocations in chronic myelogenous leukaemia.
    So CC; Wan TS; Yip SF; Chan LC
    Oncol Rep; 2008 May; 19(5):1181-4. PubMed ID: 18425374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The prognostic significance of derivative chromosome 9 deletions in chronic myeloid leukemia].
    Wu W; Li JY; Shen YF; Cao XS; Qiu HR; Xu W
    Zhonghua Nei Ke Za Zhi; 2007 May; 46(5):386-8. PubMed ID: 17637307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.